Key facts
- Innovacell (TKS: 504A)’s last known valuation is $364.2M (Feb 2026).
- It has raised $193.4M; the latest was IPO ($91.6M) in Feb 2026.
- Notable investors include SBI Investment, UntroD, HiJoJo Partners, Happiness Capital, Felicity Global Capital — 26 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Innovacell (TKS: 504A)
- ·The full record, as it builds
Funding rounds
No funding rounds for Innovacell (TKS: 504A) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innovacell (TKS: 504A)
Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Its activities include researching potential therapeutic candidates, developing formulations, and commercializing products in the markets. The company is working on the development and commercialization of the following three cell therapy pipelines targeting incontinence (fecal and urinary incontinence): ICEF15, ICEF16, and ICES13.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Employees
- 48
- Website
- innovacell.com/
- Ownership
- Publicly Held
Innovacell (TKS: 504A) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innovacell (TKS: 504A) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innovacell (TKS: 504A) in its N-PORT filings yet. We sweep new filings monthly.